IMC Funding: How Much Did They Raise & Key Investors

How Much Did IMC Raise?
Funding & Key Investors

IMC, a prominent player in the international medical cannabis sector, has successfully secured a significant capital injection, bringing its total funding to $58.5M. This latest financial milestone, characterized by a $225K strategic investment, underscores the company's ongoing commitment to expanding its footprint in the highly regulated markets of Israel and Germany. By leveraging this influx of capital, IMC continues to solidify its operational infrastructure and distribution capabilities within the global pharmaceutical landscape.

The company's growth trajectory, marked by a series of strategic financing rounds, reflects a deliberate effort to scale its medical cannabis dried flower and full-spectrum extract offerings. As the regulatory environment for medical cannabis evolves, IMC remains positioned to capitalize on increasing patient demand through its established brand portfolio, including IMC, BLKMT, and LOT420.

What is IMC?

IMC

Manufacturing

Pharmaceuticals

Drug Stores & Pharmacies

Founded in 2008 and headquartered in Vancouver, Canada, IMC operates as a specialized distributor and importer of medical cannabis products. The firm serves a critical role in the healthcare supply chain, bridging the gap between high-quality cultivation and patient access in key European and Middle Eastern markets. By maintaining rigorous standards for its product lines, IMC has established itself as a reliable partner for medical practitioners and patients alike, focusing on the therapeutic efficacy of its cannabis-derived solutions. The company's market position is defined by its ability to navigate complex international compliance frameworks while maintaining a consistent supply of premium-grade medical cannabis.

How much funding has IMC raised?

IMC has raised a total of $58.5M across 4 funding rounds:

2020

Other Financing Round

$57.2M

2023

Share Placement

$500K

Debt

$615K

2026

Debt

$225K

Other Financing Round (2020): $57.2M with participation from Super-Pharm

Share Placement (2023): $500K, investors not publicly disclosed

Debt (2023): $615K supported by L5 Capital

Debt (2026): $225K, investors not publicly disclosed

Key Investors in IMC

L5 Capital

L5 Capital is a strategic advisory and investment firm that provides comprehensive operational support, ranging from financial modeling to M&A integration, specifically targeting businesses aiming for long-term growth and IPO readiness.

Super-Pharm

Super-Pharm is a leading pharmacy chain and retail healthcare provider, leveraging its extensive distribution network to support the medical cannabis supply chain.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for IMC?

With the recent infusion of capital, IMC is poised to accelerate its strategic initiatives, focusing on market penetration and operational efficiency. The company is expected to prioritize the optimization of its distribution networks in Germany and Israel, ensuring that its medical cannabis products reach a broader patient base. Furthermore, the investment provides the necessary liquidity to explore potential M&A opportunities or partnerships that could enhance its product pipeline and technological capabilities. As IMC moves into its next phase of development, the focus will likely remain on sustainable growth, regulatory adherence, and the continued expansion of its brand presence in the competitive medical cannabis industry.

See full IMC company page

See More Financial Insights